Introduction
Antibiotic-resistant Gram-negative bacteria represent a major health threat that is further worsened by the lack of novel antibiotic structures. Tigecycline (2005) and doripenem (2007) , which are structurally related to tetracycline and carbapenem, respectively, were the last approved 'novel' antibiotics. Afterwards only a few 'new' substances representing modified b-lactams, aminoglycosides, quinolones or tetracyclines have been marketed. However, formulations overcoming resistance mechanisms by combining established antibiotics with new substances inhibiting bacterial enzymes that inactivate antibiotics, such as b-lactamase, have entered the market. 1 Proline-rich antimicrobial peptides (PrAMPs) are pharmaceutically unused antimicrobial structures killing Gram-negative pathogens by at least two distinct intracellular novel mechanisms. PrAMPs are expressed in insects, such as apidaecin (Apis mellifera), 2 drosocin (Drosophila melanogaster) 3 and oncopeltus antimicrobial peptide 4 (Oncopeltus fasciatus), 4 and in mammals (e.g. bactenecin Bac7 in bovine neutrophils). 5 Additionally, PrAMPs like Chex1Arg20 and its dimer A3-APO have been designed. 6, 7 Mechanistically, the cationic PrAMPs interact with the negatively charged bacterial surface and translocate through the outer membrane. 8 Especially long PrAMPs (.35 residues) disturb the bacterial membrane (at high concentrations) while translocating into the cytoplasm. 9 Insect-derived PrAMPs are short ($20 residues) and do not disrupt membranes, reducing harmful effects on mammalian cells. They pass the inner membrane via transporter-mediated uptake using protein SbmA 10 and the efflux pump MdtM (drug/H + antiporter). 11 Interestingly, SbmA is present in phylogenetically distant species of Gramnegative bacteria, but absent in Pseudomonas aeruginosa. 12 Still, optimized analogues of the short PrAMPs apidaecin and oncocin are active against P. aeruginosa without disrupting the bacterial membrane. 13, 14 This selective bacterial uptake usually prevents the translocation of short PrAMPs into mammalian cells, providing higher margins of safety that are further increased by their specific intracellular targets. 15 Chaperone DnaK and the bacterial 70S ribosome are known targets of all PrAMPs, such as apidaecin analogue Api88 and oncocin analogue Onc112. 17 We classified PrAMPs by their different target mechanisms as apidaecin-type PrAMPs (e.g. Api88), [18] [19] [20] which inhibit protein translation by trapping release factors at the ribosome, 21 and oncocin-type PrAMPs (e.g. Onc112), which inhibit translation by blocking and destabilizing the initiation complex. [22] [23] [24] [25] Besides their low cytotoxicity, lack of haemolytic activity and good in vivo tolerance, the PrAMPs A3-APO, apidaecins, Bac7, drosocin and oncocin possess high efficacies in different infection models against Escherichia coli, 16,26-28 Klebsiella pneumoniae,
29
Salmonella enterica 30 and Acinetobacter baumannii 31 when administered intravenously, 28 intraperitoneally, 16, 26, 27, 29, 30 intramuscularly 31, 32 or subcutaneously. 33 However, the pharmacokinetics does not explain the in vivo efficacy, 34, 35 at least in comparison with small-molecule antibiotics. Only continuous subcutaneous infusion of Api137 achieved stable plasma levels of $6 mg/L, which appeared reasonable to kill bacteria with corresponding MICs (D. Knappe, K. Adermann and R. Hoffmann, unpublished results).
Remarkably, Craig 36 noted already in 1991 that MICs and MBCs obtained by standard in vitro methods are insufficient in predicting in vivo antibiotic activity. Instead, further pharmacodynamic parameters have to be considered, such as post-antibiotic effect (PAE), post-antibiotic leucocyte enhancement (PALE) and minimal antibacterial concentration (MAC). [37] [38] [39] PAE indicates the persistent growth of bacteria briefly exposed to antibiotics independently of host defence mechanisms. The PAE depends on different effects in vivo, such as persistent high drug concentrations at the site of infection, delayed recovery of enzyme and protein activity, changes in cell morphology, metabolism, cell receptors and ribosome density, prolonged growth and generation times, higher susceptibility to phagocytes and the influence of virulence factors like haemolysin. [36] [37] [38] Pharmacodynamically, antibiotics are divided into three groups. 37, 39, 40 The first group act mainly time dependently and are slowly bactericidal (e.g. b-lactams, vancomycin) with no or only low PAE. Their efficacy depends typically on the time they are present at plasma levels above MIC, demanding continuous or intermittent dosing. 39 Group 2 are concentration-dependently bactericidal (e.g. aminoglycosides, fluoroquinolones) with C max as the limiting factor. As bactericidal activity and PAE increase with increasing dose, typically a single maximal dose is administered. The third group contains predominantly bacteriostatic antibiotics (e.g. macrolides) with moderate to prolonged PAE. Their action is concentration dependent rather than time dependent, with the AUC as the most important parameter. 37, 39, 40 It is difficult to assign PrAMPs to any of these groups, although apidaecins appear to be described best as concentration-dependent (group 2) and oncocins as time-dependent antibiotics (group 1). 35 In order to further classify short PrAMPs and to provide a better correlation of in vitro and in vivo data, the PAEs of 10 PrAMPs were determined in vitro in comparison with chloramphenicol, gentamicin and kanamycin (also ribosomal inhibitors) with known PAEs. [41] [42] [43] [44] Materials and methods Peptides were synthesized in-house as described previously. 3, 4, 16, 34, 35 Water was purified on a Purelab Ultra water purification system (electrical resistivity .182 kXÁm; organic content ,2 ppb). E. coli BW25113 was obtained from the Keio collection (GenoBase, http://ecoli.aist-nara.ac.jp). 45 E. coli MC4100 was kindly provided by Professor Dr Bernd Bukau (Heidelberg, Germany). E. coli ATCC 25922 (DSM1103), K. pneumoniae ATCC 10031 (DSM 681) and P. aeruginosa ATCC 27853 (DSM 1117) were purchased from Leibniz Institute DSMZ -German Collection of Microorganisms and Cell cultures (Braunschweig, Germany).
Antimicrobial activity
Peptides or antibiotics were plated in a 2-fold dilution series (50 lL/well) in MHB (5.75 g/L, 25% MHB) into 96-well F-bottom polystyrene plates (Greiner Bio-One GmbH, Frickenhausen, Germany, #655180). E. coli strains BW25113, MC4100 and ATCC 25922 and P. aeruginosa ATCC 27853 were grown overnight in nutrient broth and K. pneumoniae ATCC 10031 in TSB (4 mL, 200 rpm, 37 C). Bacteria were diluted with 25% MHB to an OD 600nm of $0.05 and incubated to reach a logarithmic growth rate between 1.5 and 4h ( Figure S1 , available as Supplementary data at JAC Online). Bacterial suspensions were adjusted to 1.5%10 7 cells/mL and added to each well (50 lL) to obtain a final cell density of 7.5%10 6 cells/mL. After incubation (22+2 h, 37 C) the turbidity was measured at 595 nm with a Sunrise microplate reader (Tecan Deutschland GmbH, Crailsheim, Germany) for E. coli strains BW25113 and MC4100 or a SpectraMax 340 PC (Molecular Devices, Sunnyvale, CA, USA) for all other strains. MIC values were defined as the lowest peptide concentration inhibiting bacterial growth and were measured at least twice as triplicates on two different days.
PAE
Peptides or antibiotics were dissolved in water to final concentrations corresponding to 0.1 %, 0.4 %, 1 % and 4 % MIC into a sterile 96-well polystyrene V-bottom plate (3 lL/well; Greiner Bio-One GmbH, #651180). Water (3 lL/well) was used as negative control. Bacteria were grown and adjusted to 7.5%10 6 cells/mL, as described above, and added simultaneously to each well (147 lL) using the Steinbrenner Liquidator96 V R (Mettler Toledo, Gießen, Germany). All following steps were performed simultaneously using the Liquidator96 V R . After incubation (1 h, 37 C, 600 rpm, Eppendorf Thermomixer), plates were centrifuged (1238 g, 10min, 4 C), the supernatant (130 lL/well) was removed and cells were suspended in fresh medium (room temperature, 150 lL/well). Plates were centrifuged again, the supernatant was removed and cells were again suspended in fresh medium (130 lL, 37 C). An aliquot (100 lL) was transferred into anti-edgeeffect polystyrene F-bottom plates (Eppendorf AG, Hamburg, Germany, #0030730.119) using 8 mL of water at the edge of the plate. The absorbance of the covered plate was recorded at 600 nm every 20 min after shaking (5 s) for 22 h (37 C) using a Paradigm V R microplate reader or a SpectraMax 340 PC (Molecular Devices). Cell viability was determined simultaneously on agar (37 C; overnight) using the remaining cell suspension and appropriate dilutions (10 lL for each one-third of a 10 cm plate).
The PAE was calculated as the difference between the time T needed for a cell culture incubated with an antibiotic substance to reach halfmaximum absorbance of the control culture and the time C that the control culture needed to reach half-maximum absorbance of the stationary phase. The growth curves were fitted using a sigmoidal dose-response fit with variable slope (GraphPad Prism) according to equation (1) . The software provides values for Bottom (minimum absorbance of the fit), Top (maximum absorbance), LogEC50 and HillSlope with the absorbance Y at the corresponding time X. The half-maximum absorbance (Y max1/2 ) of the control was calculated using equation (2) and inserted in equation (3) Holfeld et al.
to calculate the time for the treated culture (T) and the control (C). Equation (3) was transposed from equation (1).
For P. aeruginosa no clear stationary phase was observed and thus an automatic fit was impossible ( Figure S2 ). Thus, Y was determined manually and Microsoft Excel was used to identify the closest absorbance of the sample to Y max1/2 and the corresponding times C and T.
Results

Antimicrobial activity
A prerequisite for determining PAEs of antibiotic substances is the MIC value determined under identical conditions. As in previous studies on PrAMPs, [16] [17] [18] [19] [20] 26 we used diluted (25%) MHB medium, which provides more reliable MIC values than full-strength MHB and allows much better prediction of the in vivo efficacy of PrAMPs. The MICs of most PrAMPs ranged from 2 to 8 mg/L for E. coli strains BW25113, MC4100 and ATCC 25922 and K. pneumoniae ATCC 10031 (Table 1) . Only Bac7(1-60), drosocin Hyp5 and oncocin Onc72 were less active against some E. coli strains. The MIC values of gentamicin, kanamycin and chloramphenicol ranged from 0.25 to 2 mg/L. Considering the mean molecular weights for PrAMPs (2000 g/mol) and antibiotics (500 g/mol), similar molar antimicrobial activities were obtained against Enterobacteriaceae. Bac7(1-60) and A3-APO were equally active against P. aeruginosa ATCC 27853, whereas short PrAMPs were at least 16-fold less active (MIC !32 mg/L; Table 1 ). The better activity of long PrAMPs against P. aeruginosa probably relates to their effect on membranes, which is independent of transporter SbmA, which is absent in P. aeruginosa.
9,12 The 4-fold higher MIC values of kanamycin and chloramphenicol are in accordance with the intrinsic resistance of P. aeruginosa to many antibiotics, whereas gentamicin remained highly active (MIC 1 mg/L). The MIC values of all three antibiotics determined here were in agreement with the literature. 46 
PAE
Bacterial cultures were incubated with PrAMPs and antibiotic comparators at concentrations corresponding to 0.1 %, 0.4 %, 1 % and 4 % the respective MIC. Utilization of the 96-channel pipetting system enabled reproducible high-throughput analyses of 32 samples in triplicate on a 96-well microtitre plate (Figure 1 ). Besides similar curve shapes of the triplicates within one experiment, the PAE values were typically very reproducible among experiments on different days, e.g. 3.7+0.6 h (at 0.4 % MIC) and 11.8+2.4 h (at MIC) for Api137 and E. coli BW25113 (Figure 1b and Table S1 ). If bacterial growth remained ,50% of the maximum growth of the control during the 14 h observation period, e.g. for Api137 at 4 % MIC (Figure 1b) , the PAE was set to 14.0 h (strong PAEs).
E. coli incubated with PrAMPs at 0.1 % MIC provided PAEs ,4 h, e.g. 3.4+0.9 and 3.7+0.1 h for Onc72 against E. coli BW25113 and MC4100, respectively ( Figure 2 and Table S1 ). The PAE typically remained ,4 h when the peptide concentration was increased to 0.4 % MIC. Onc72 and A3-APO showed stronger effects against E. coli strains BW25113 (5.6+0.8 and 4.6+0.4 h, respectively) and MC4100 (9.2+0.7 and 5.3+0.6 h, respectively) and pyrrhocoricin against E. coli ATCC 25922 (4.4+0.2 h). At MIC, the PAE increased for Onc72, Api88, Api137, Bac7(1-60) and Chex1Arg20 to .8 h for Post-antibiotic effect of PrAMPs JAC at least one of the three E. coli strains and for the longer peptides Bac7(1-60) and A3-APO to .12 h against E. coli strains BW25113 and MC4100. In contrast, gentamicin, kanamycin and chloramphenicol reached maximal PAEs of only 1.3 h, drosocin Hyp5 reached 4.7 h and pyrrhocoricin reached 6.2 h against all three E. coli strains. The highest PrAMP concentrations (4 % MIC) always resulted in PAEs .9 h, often even .12 h. The largest variations among the three E. coli strains were obtained for drosocin Hyp5 and pyrrhocoricin. The PAE of drosocin Hyp5 against E. coli ATCC 25922 was relatively strong at 4 % MIC (13.3+4.7 h), but weak for BW25113 (4.1+0.2 h) and MC4100 (2.9+0.9 h). Pyrrhocoricin showed strong PAEs against E. coli ATCC 25922 (14.4+3.0 h) and MC4100 (11.0+2.4 h), but a weak PAE against BW25113 (3.0+1.1 h). The PAEs determined for 4 % MIC were high for gentamicin (8-14 h), medium for kanamycin (6-10 h) and very low for chloramphenicol (2 h). All PrAMPs besides drosocin Hyp5 and pyrrhocoricin and all three small molecules showed similar PAEs against the E. coli strains. The PAEs of PrAMPs and standard antibiotics against K. pneumoniae ATCC 10031 were consistently ,3 h at 0.1 % MIC, with the highest value obtained for Api88 (2.6+0.3 h) ( Figure 3 and Table S1 ). Fourfold higher concentrations increased the PAEs of Api88 (7.7+0.4 h), Api137 (4.2+0.6 h) and A3-APO (4.4+0.9 h) significantly, whereas the PAEs of all other compounds remained ,4 h. Interestingly, at MIC the PAE increased for Api88 (18.8+1.2 h), Api795 (13.4+4.7 h), Bac7(1-60) (18.2+3.3 h) and A3-APO (13.1+2.7 h) to .12 h, but for all other peptides remained below 12 h, with drosocin Hyp5 showing the weakest PAE of 4.2+0.5 h. The PAEs of the three small-molecule antibiotics were even lower (1.3-3.6 h at MIC). At high concentrations (4 % MIC) most PrAMPs exhibited strong PAEs against K. pneumoniae (!18 h); only drosocin Hyp5 (10.3+0.6 h), pyrrhocoricin (9.8+0.5 h) and Chex1Arg 20 (6.6+0.7 h) showed lower values. Note that at these high concentrations both aminoglycosides (gentamicin and kanamycin) exhibited as strong PAEs as the best PrAMPs (!19.5 h), whereas the PAE of chloramphenicol remained at 3.5+0.2 h.
When P. aeruginosa ATCC 27853 was inhibited with small-molecule antibiotics at concentrations up to MIC, the PAEs remained ,4 h ( Figure 4 and Table S1 ). This was also true for PrAMPs at sub-MIC, but at MIC the PAEs of PrAMPs ranged from 4.3+0. Holfeld et al.
lower PAEs than the PrAMPs (7.8+0.7 and 8.9+1.1 h). Chloramphenicol showed the weakest PAE of all compounds (2.1+0.7 h).
PAE and viable cell count
The viable cell counts of E. coli and K. pneumoniae usually decreased at MIC by at least 1 log unit within an incubation period of 1 h and even further for conditions providing long PAEs ( Figures S3, S4 and S5) . The viable count of the P. aeruginosa control was much lower (2.7+1.1%10 5 cfu/mL) than the mean of all other strains (5.1+2.2%10 6 cfu/mL). Chloramphenicol always showed bacteriostatic activities. Drosocin Hyp5 and pyrrhocoricin were also bacteriostatic except for E. coli ATCC 25922 (P. aeruginosa not tested). Interestingly, Chex1Arg20 was bacteriostatic solely against K. pneumoniae, for which it also exhibited the lowest PAE. Gentamicin and kanamycin were always bactericidal at 4 % MIC. Strong bactericidal activities were observed for the long PrAMPs Bac7(1-60) and A3-APO, which can be explained by their dual mode of action, i.e. intracellular inhibition at MIC and increasing membrane permeability at peptide concentrations above the MIC. 9 Interestingly, the bactericidal effects obtained for PrAMPs against E. coli ATCC 25922 and P. aeruginosa exceeded the effects of aminoglycosides. PAEs observed when treating E. coli strains BW25113 (top), MC4100 (middle) and ATCC 25922 (bottom) (7.5%10 6 cells/mL; 1 h, 37 C, 600 rpm) with PrAMPs and antibiotic comparators at concentrations of 0.1 %, 0.4 %, 1 % and 4 % MIC (white, light grey, dark grey and black bars, respectively). Experiments were done twice in triplicate on different days. Hash signs indicate that none of the six individual curves reached half-maximum absorbance of the control within 22 h, whereas dollar signs indicate that this threshold was not reached in one to five replicates. For details see Table S1 .
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Discussion
There are several studies about PAEs, but standardized protocols are missing. Thus, the bacteria used, bacterial and antibiotic concentrations, exposure times and methods for drug removal vary in the literature, with only a few publications relying on comparable conditions (for a detailed discussion see the Supplementary Discussion available as Supplementary data at JAC Online). 37 E. coli ATCC 25922 is commonly used in PAE studies and the MIC values of gentamicin (0.5 mg/L) and chloramphenicol (2 mg/L) measured here for this strain were comparable to previous studies. [42] [43] [44] However, the PAEs of 8.0+0.7 h (4 % MIC) and 2.6+0.6 h (1 % MIC) obtained here for gentamicin lasted much longer than in previous reports, i.e. 1.1 h (4 % MIC) and 0.5 h (1 % MIC), 44 but were close to the 2 and 4 h reported for gentamicin at 5 % MIC. 42, 47 The PAE of 1 h reported for bacteriostatic chloramphenicol (5 % MIC) was close to the 2.0+0.5 h measured here at 4 % MIC. 42 These differences are most likely related to different laboratory routines, especially the different cell densities. Our sensitive method, which enables the determination of PAEs in $20 h, relied on the cell density recommended for MIC assays, i.e. 7.5%10 5 cells/mL. In contrast, the literature relies on much higher cell densities of 2%10 7 to 2%10 8 cells/mL, which results also in higher MIC values when measured for these conditions. 13, 48 Importantly, the highthroughput method described here enabled determination of the PAE for four different concentrations of 10 PrAMPs and three antibiotic comparators with high reproducibility.
Unexpectedly, the PAEs of several PrAMPs determined at 0.4 % MIC exceeded 4 h, i.e. Onc72 (!5.6 h) and A3-APO (!4.6 h) against E. coli MC4100 and BW25113, pyrrhocoricin (4.4 h) against E. coli ATCC 25922 and Api88 (7.7 h) and Api137 (4.2 h) even against K. pneumoniae ATCC 10031. The PAEs determined for PrAMPs at MIC lasted typically for .4 h, with the highest PAEs (!10 h) obtained against at least one E. coli strain and Figure 3 . PAEs obtained by incubating K. pneumoniae ATCC 10031 (7.5%10 6 cells/mL; 1 h, 37 C, 600 rpm) with PrAMPs and antibiotic comparators at concentrations of 0.1 %, 0.4 %, 1 % and 4 % MIC (white, light grey, dark grey and black bars, respectively). Experiments were done twice in triplicate on different days. The PAE was calculated as T # C, with C being the time the control needed to reach half-maximum absorbance and T the time necessary for the treated sample to reach the half-maximum absorbance of the control. Hash signs indicate that none of the six individual curves reached half-maximum absorbance of the control within 22 h, whereas dollar signs indicate that this threshold was not reached in one to five replicates. For details see Table S1 . 6 cells/mL; 1 h, 37 C, 600 rpm) when incubated with PrAMPs and antibiotic comparators at concentrations of 0.1 %, 0.4 %, 1 % and 4 % MIC (white, light grey, dark grey and black bars, respectively). Experiments were done at least twice in triplicate on different days. The PAE was calculated as T # C with C being the time the control needed to reach half-maximum absorbance and T the time necessary for the treated sample to reach the half-maximum absorbance of the control. Dollar signs indicate that one to five individual curves did not reach the half-maximum absorbance of the control within 22 h. For details see Table S1 .
K. pneumoniae ATCC 10031 for Api88, Api137, Bac7(1-60) and A3-APO and for Chex1Arg20 against E. coli BW25113 and MC4100. The effects seen for small-molecule antibiotics at MIC were considerably weaker. Only gentamicin exceeded 4 h against E. coli MC4100. As expected, the PAEs further increased for higher peptide concentrations and almost all substances showed values .10 h against all strains at 4 % MIC, which is partially related to the bactericidal effect, i.e. reduced viable cell numbers after the incubation period. The same was true for gentamicin and kanamycin, possessing PAEs comparable to PrAMPs, whereas the PAEs of chloramphenicol remained ,4 h, indicating its bacteriostatic properties. As a statistical analysis considering all tested substances and bacterial strains would provide a very large data set, we compared the apidaecin and oncocin derivatives, which possess similar structures and properties, as one group with the three antibiotics (small molecules) as a second group. The apidaecin/oncocin group showed significantly higher PAEs than the group of antibiotics at 0.4 % and 1 % MIC against all strains, underlining their high therapeutic potential ( Figure S6 ).
Drosocin Hyp5 and pyrrhocoricin exhibited the lowest PAEs among the PrAMPs, comparable to gentamicin and kanamycin. The PAEs of the other PrAMPs increased in the following order: oncocins , apidaecins , Bac7(1-60) " A3-APO. The long-lasting PAEs of the two long PrAMPs can be explained by their additional effects on bacterial membranes. 9, 12 Interestingly, some PrAMPs reduced the viable cell counts after an incubation period of 1 h at 4% MIC more than the bactericidal aminoglycosides. Considering the long PAEs of PrAMPs observed here at MIC and sub-MIC and the bactericidal activity indicated by decreasing viable cell counts, PrAMPs probably belong to group 2 of the pharmacodynamic classification scheme, i.e. antibiotics with concentration-dependent bactericidal action and prolonged PAEs, such as aminoglycosides, with C max as limiting factor. 39 Although the strong PAEs were unexpected, a recent study on bacterial uptake perfectly correlates to this observation. Apidaecins and oncocins bind rapidly to E. coli and translocate into the cytoplasm within minutes, as indicated by labelled peptides using flow cytometry and confirmed by unlabelled peptides using liquid chromatography. 11, 48, 49 The authors could show that internalized Api137 remains in the cells without leaking into fresh medium using conditions close to the PAE assay applied here. 48 In contrast, Onc112 was detected in the fresh medium. However, the authors argued that Onc112 might be released mostly from non-viable cells. These uptake studies and the current PAE data can nicely explain the apparent discrepancy between high in vivo efficacy and relatively low plasma levels. 29, 34, 35 Presumably, PrAMPs enter bacteria rapidly in the host and inhibit the 70S ribosomes, as indicated by the strong PAE, even at MIC and partially also at sub-MIC concentrations. Thus, bacterial growth is stopped, allowing the host immune system to eradicate the pathogens before they start to grow again.
It should be noted that Laszlo Otvos's group has provided compelling evidence that their designer peptide A3-APO stimulates the mouse immune system as a third mode of action. 50 In this respect, the efficacy of A3-APO might be best described as an artificial host defence peptide that relies mostly on immunomodulation, as demonstrated in wound and systemic infection models for Propionibacterium acnes, Staphylococcus aureus and Proteus mirabilis. 7, 51, 52 Most recently, they showed that pre-infection treatment with transdermally administered A3-APO protects mice against intraperitoneal infections with A. baumannii. 53 Apidaecins and oncocins have not been studied in vivo for immunomodulatory effects yet. In vitro, neither type of PrAMP showed immunomodulatory effects on unstimulated and LPS-stimulated murine dendritic cells or macrophages. 54 In contrast, reduction of LPS-induced TNFa release of human macrophages and monocytes by apidaecins indicates a mild anti-inflammatory effect. 55 Independently, Tavano et al. 56 reported for apidaecin 1b a differential immunomodulation of human macrophages, dendritic cells and macrophages. Additionally, A3-APO increases the levels of antiinflammatory cytokines IL-4 and IL-10 in human peripheral blood mononuclear cells, possibly indicating a reduction in inflammation at the site of an infection. 52 The PAEs presented here provide an additional hypothesis besides immunomodulatory effects that can explain the good in vivo efficacies of PrAMPs, which are not wholly expected, in different infection models despite the fast clearance rates reported for apidaecins, oncocins, A3-APO and Chex1Arg20 in mice. This highlights again that MIC values determined for AMPs in vitro cannot be simply used to predict in vivo efficacies, as often assumed in the literature. Instead MIC values should be seen as one important criterion among other parameters to be considered.
